ArticleOncogene2014
DRR regulates AKT activation to drive brain cancer invasion.
Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- DRR1 promotes neuroblastoma cell differentiation by regulating CREB expression.Pediatric research · 2023Article
- Nucleic acid drug vectors for diagnosis and treatment of brain diseases.Signal transduction and targeted therapy · 2023Review
- Identification of the Putative Tumor Suppressor Characteristics of FAM107AFrontiers in oncology · 2022Article
- Identification of FAM107A as a potential biomarker and therapeutic target for prostate carcinoma.American journal of translational research · 2021Article
- Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy.Nature communications · 2020Article
- Effect of Sugar 2',4'-Modifications on Gene Silencing Activity of siRNA Duplexes.Nucleic acid therapeutics · 2019Article
- Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Review
- Loss of Trem2 in microglia leads to widespread disruption of cell coexpression networks in mouse brain.Neurobiology of aging · 2018Article
- Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells.Molecular therapy. Nucleic acids · 2018Article
- Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs.Molecular cancer therapeutics · 2018Article
- A novel nuclear complex of DRR1, F-actin and COMMD1 involved in NF-κB degradation and cell growth suppression in neuroblastoma.Oncogene · 2017Article
- Impaired neurodevelopment by the low complexity domain of CPEB4 reveals a convergent pathway with neurodegeneration.Scientific reports · 2016Article
- Securin promotes migration and invasion via matrix metalloproteinases in glioma cells.Oncology letters · 2015Article
- Synthesis and properties of 2'-deoxy-2',4'-difluoroarabinose-modified nucleic acids.The Journal of organic chemistry · 2015Article
- PCAF-mediated Akt1 acetylation enhances the proliferation of human glioblastoma cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Family with sequence similarity 107: A family of stress responsive small proteins with diverse functions in cancer and the nervous system (Review).Biomedical reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Glioblastoma (GBM) is the most common and invasive adult brain cancer. The rapid invasion of cancer cells into the normal brain is a major cause of treatment failure, yet the mechanisms that regulate this process are poorly understood. We have identified a novel mechanism of brain cancer invasion. We show that downregulated in renal cell carcinoma (DRR), which is newly expressed in invasive gliomas, recruits AKT to focal adhesions. This DRR- induced pathological relocalization of AKT bypasses commonly altered upstream signaling events and leads to AKT activation and invasion. We also developed an oligonucleotide therapeutic that reduces DRR expression and prevents glioma invasion in an in vivo preclinical model of the disease. Our findings identify DRR as a novel GBM target and show that oligonucleotides targeting DRR is a novel therapeutic approach for the treatment of DRR-positive GBMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.